Cargando…

Somatic mutations in SF3B1 aberrant‐negative MDS‐RS most commonly involved in TP53 genes

Detalles Bibliográficos
Autores principales:	Li, Xiao, Xu, Feng, Wu, Ling‐Yun, Guo, Juan, He, Qi, Zhang, Zheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189334/ https://www.ncbi.nlm.nih.gov/pubmed/35582925 http://dx.doi.org/10.1111/jcmm.17350

Ejemplares similares

Immunohistochemical correlates of TP53 somatic mutations in cancer
por: Murnyák, Balázs, et al.
Publicado: (2016)

MDS and TP53: When One Hit Just Isn’t Enough…
por: Kent, David G.
Publicado: (2020)

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS
por: Hofman, Isabel Juliana F., et al.
Publicado: (2022)

A novel TP53 somatic mutation involved in the pathogenesis of pediatric choroid plexus carcinoma
por: Lv, Sheng-Qing, et al.
Publicado: (2012)

Immunological Role of TP53 Somatic Mutation Classification in Human Cancers
por: Fang, Jianfei, et al.
Publicado: (2023)

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia
por: Chitadze, Guranda, et al.
Publicado: (2023)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency
por: Cole, Alexander J., et al.
Publicado: (2017)

Somatic Mutations of TP53 and Prognostic Factors for Primary Operable Breast Cancer: Correspondence
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
por: Ragu, Mohana Eswari, et al.
Publicado: (2023)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

P713: EXPLORING CLONAL COMPETITION THROUGH 12-YEAR FOLLOW-UP OF AN MDS-RS PATIENT WITH DUAL SF3B1 MUTATIONS
por: Moura, Pedro, et al.
Publicado: (2023)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients
por: Olivier, M, et al.
Publicado: (2005)

The TP53 Codon 72 Arginine Polymorphism Is Found with Increased TP53 Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients
por: Moe, Svein Erik, et al.
Publicado: (2023)

Low density DNA microarray for detection of most frequent TP53 missense point mutations
por: Rangel-López, Angélica, et al.
Publicado: (2005)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2022)

Somatic SF3B1 hotspot mutation in prolactinomas
por: Li, Chuzhong, et al.
Publicado: (2020)

Somatic TP53 Mutations Are Detectable in Circulating Tumor DNA from Children with Anaplastic Wilms Tumors()()
por: Treger, Taryn D., et al.
Publicado: (2018)

TP53 rs1042522 polymorphism and early-onset breast cancer
por: Icen-Taskin, Irmak, et al.
Publicado: (2020)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer
por: Chang, Pi-Yueh, et al.
Publicado: (2017)

SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS
por: Huang, Yumin, et al.
Publicado: (2018)

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
por: Huber, Sandra, et al.
Publicado: (2022)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

MON-519 In Silico Analysis of rs1042522 and rs1042522 Polymorphic Variants of TP53 Gene
por: Bó, Izabela Dal, et al.
Publicado: (2020)

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
por: McCubrey, James A., et al.
Publicado: (2022)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

Multimodality MRI radiomics analysis of TP53 mutations in triple negative breast cancer
por: Sun, Kun, et al.
Publicado: (2023)

Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222
por: Enciso-Mora, V, et al.
Publicado: (2013)

Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs
por: Asimomitis, Georgios, et al.
Publicado: (2022)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gfdd2li407uir6qnolhg74u1e6